A retrospective, observational, single-center study assessing the immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment
Latest Information Update: 05 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
Most Recent Events
- 05 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology